Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:34PM ET
40.38
Dollar change
+0.21
Percentage change
0.52
%
IndexRUT P/E- EPS (ttm)-2.52 Insider Own11.38% Shs Outstand55.59M Perf Week-1.08%
Market Cap2.47B Forward P/E- EPS next Y-3.35 Insider Trans-6.61% Shs Float54.16M Perf Month-6.64%
Income-146.96M PEG- EPS next Q-0.71 Inst Own90.16% Short Float15.37% Perf Quarter55.13%
Sales78.59M P/S31.40 EPS this Y-19.14% Inst Trans3.67% Short Ratio10.29 Perf Half Y173.76%
Book/sh7.11 P/B5.68 EPS next Y-11.66% ROA-24.93% Short Interest8.33M Perf Year43.45%
Cash/sh6.13 P/C6.58 EPS next 5Y1.90% ROE-33.21% 52W Range9.60 - 45.31 Perf YTD58.60%
Dividend Est.- P/FCF- EPS past 5Y-39.18% ROI-31.05% 52W High-10.88% Beta2.27
Dividend TTM- Quick Ratio4.73 Sales past 5Y241.22% Gross Margin95.46% 52W Low320.62% ATR (14)1.84
Dividend Ex-Date- Current Ratio4.73 EPS Y/Y TTM12.49% Oper. Margin-210.62% RSI (14)52.85 Volatility3.77% 4.64%
Employees187 Debt/Eq0.21 Sales Y/Y TTM67.84% Profit Margin-186.99% Recom1.75 Target Price50.93
Option/ShortYes / Yes LT Debt/Eq0.20 EPS Q/Q59.24% Payout- Rel Volume0.21 Prev Close40.17
Sales Surprise14.17% EPS Surprise38.04% Sales Q/Q196.70% EarningsFeb 22 BMO Avg Volume809.61K Price40.38
SMA20-2.14% SMA507.86% SMA20065.64% Trades Volume86,550 Change0.52%
Date Action Analyst Rating Change Price Target Change
Feb-15-24Initiated Wolfe Research Peer Perform
Jan-04-24Upgrade JP Morgan Neutral → Overweight
Jan-03-24Downgrade BofA Securities Buy → Neutral $45 → $30
Dec-19-23Downgrade Wells Fargo Overweight → Equal Weight $26
Jun-30-23Initiated Truist Buy $50
May-05-23Upgrade Raymond James Mkt Perform → Outperform
Dec-06-22Downgrade Credit Suisse Outperform → Neutral $47 → $32
Nov-08-22Initiated Raymond James Mkt Perform
Aug-15-22Initiated Jefferies Buy $40
Aug-03-22Initiated Goldman Buy $40
Mar-08-24 10:00AM
Mar-04-24 11:27PM
Feb-28-24 07:00AM
Feb-23-24 11:59AM
Feb-22-24 11:24PM
07:35AM Loading…
07:35AM
07:00AM
Feb-21-24 11:52PM
Feb-15-24 10:00AM
07:00AM
Feb-10-24 02:56AM
Jan-31-24 07:00AM
Jan-24-24 12:20AM
Jan-17-24 08:00AM
Jan-09-24 09:17AM
09:15AM Loading…
09:15AM
Jan-05-24 04:03PM
06:00AM
Jan-04-24 04:01PM
07:00AM
Jan-02-24 07:00AM
Dec-22-23 10:45AM
Dec-18-23 02:58PM
Dec-13-23 07:00AM
Dec-10-23 09:00PM
Dec-08-23 11:13AM
Dec-07-23 07:00AM
Nov-13-23 11:00AM
Nov-07-23 09:05AM
Nov-05-23 02:38PM
09:00AM Loading…
Nov-02-23 09:00AM
08:43AM
07:00AM
Nov-01-23 07:00AM
Oct-27-23 07:00AM
Oct-26-23 10:02AM
07:00AM
Oct-19-23 09:35AM
Oct-18-23 09:35AM
Oct-16-23 07:00AM
Oct-04-23 06:23AM
Oct-03-23 04:48PM
Sep-18-23 07:00AM
Aug-28-23 07:00AM
Aug-03-23 08:25AM
07:00AM
Jul-28-23 03:57PM
Jul-27-23 07:00AM
Jul-09-23 09:09AM
Jun-22-23 08:30AM
Jun-14-23 02:30AM
Jun-09-23 06:00PM
03:00AM
Jun-01-23 07:00AM
May-29-23 12:24PM
May-22-23 07:00AM
May-19-23 07:00AM
May-18-23 07:00AM
May-14-23 02:57PM
May-09-23 03:15PM
May-04-23 08:25AM
07:00AM
Apr-19-23 11:11AM
Apr-11-23 07:00AM
Apr-09-23 01:19PM
Mar-09-23 03:00PM
Mar-03-23 11:40AM
Mar-01-23 07:00AM
Feb-24-23 02:53AM
Feb-23-23 08:25AM
07:00AM
Feb-01-23 07:00AM
Jan-31-23 08:00AM
Jan-30-23 07:26AM
Jan-23-23 04:14AM
Jan-17-23 06:27AM
Jan-10-23 07:00AM
Jan-09-23 12:00PM
Jan-04-23 07:00AM
Jan-03-23 07:00AM
Dec-21-22 04:57PM
Dec-20-22 10:33AM
Dec-15-22 10:27AM
Dec-14-22 04:09PM
01:44PM
10:00AM
07:57AM
07:00AM
Dec-12-22 10:00AM
Dec-11-22 10:00AM
Dec-01-22 07:00AM
Nov-09-22 06:16AM
Nov-05-22 08:33AM
Nov-03-22 08:35AM
07:05AM
07:00AM
Oct-20-22 07:30AM
Oct-19-22 09:42AM
Oct-13-22 04:15PM
Sep-15-22 07:30AM
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Booth BruceDirectorMar 15 '24Sale40.4671,7642,903,336806,697Mar 15 07:23 PM
Booth BruceDirectorMar 14 '24Sale39.9855,7792,229,927819,151Mar 15 07:23 PM
Booth BruceDirectorMar 13 '24Sale42.23139,2555,880,415828,830Mar 13 07:52 PM
Atlas Venture Fund X, L.P.10% OwnerMar 13 '24Sale42.23115,0904,859,9934,676,075Mar 13 07:53 PM
Atlas Venture Fund X, L.P.10% OwnerMar 13 '24Sale42.2324,1651,020,422828,830Mar 13 07:53 PM
Booth BruceDirectorMar 12 '24Sale41.98162,9186,838,813852,995Mar 13 07:52 PM
Atlas Venture Fund X, L.P.10% OwnerMar 12 '24Sale41.98134,6475,652,0724,791,165Mar 13 07:53 PM
Atlas Venture Fund X, L.P.10% OwnerMar 12 '24Sale41.9828,2711,186,741852,995Mar 13 07:53 PM
Booth BruceDirectorMar 11 '24Sale42.8551,1842,193,148881,266Mar 13 07:52 PM
Atlas Venture Fund X, L.P.10% OwnerMar 11 '24Sale42.8542,3021,812,5864,925,812Mar 13 07:53 PM
Atlas Venture Fund X, L.P.10% OwnerMar 11 '24Sale42.858,882380,562881,266Mar 13 07:53 PM
Jacobs Bruce N.Chief Financial OfficerMar 04 '24Sale41.863,934164,664142,351Mar 04 06:12 PM
Gollob JaredChief Medical OfficerMar 04 '24Sale41.863,344139,96795,740Mar 04 06:21 PM
Albers Jeffrey W.DirectorFeb 21 '24Option Exercise10.344,38545,3414,385Feb 21 06:46 PM
Albers Jeffrey W.DirectorFeb 21 '24Sale39.054,385171,2270Feb 21 06:46 PM
Albers Jeffrey W.DirectorFeb 20 '24Option Exercise10.346156,359615Feb 21 06:46 PM
Albers Jeffrey W.DirectorFeb 20 '24Sale39.0761524,0310Feb 21 06:46 PM
Gollob JaredChief Medical OfficerFeb 09 '24Option Exercise2.0846,13795,965120,846Feb 09 07:47 PM
Gollob JaredChief Medical OfficerFeb 09 '24Sale35.5046,1371,638,07174,709Feb 09 07:47 PM
Albers Jeffrey W.DirectorJan 23 '24Option Exercise10.3410,000103,40010,000Jan 23 07:37 PM
Albers Jeffrey W.DirectorJan 23 '24Sale30.0510,000300,4700Jan 23 07:37 PM
Chiniara EllenChief Legal OfficerJan 04 '24Sale22.583,29574,41634,205Jan 05 05:15 PM
Mainolfi NelloChief Executive OfficerJan 02 '24Option Exercise2.089,00018,720615,570Jan 02 05:43 PM
Mainolfi NelloChief Executive OfficerNov 03 '23Option Exercise2.0820,00041,600606,570Nov 06 06:00 PM
BVF PARTNERS L P/ILDirectorNov 03 '23Buy14.07197,6992,781,4072,656,191Nov 06 06:07 PM
BVF PARTNERS L P/ILDirectorNov 02 '23Buy11.64216,4062,519,9182,552,306Nov 06 06:07 PM
Mainolfi NelloChief Executive OfficerAug 08 '23Option Exercise2.0812,00024,960586,570Aug 08 04:30 PM
Jacobs Bruce N.Chief Financial OfficerJun 02 '23Option Exercise2.0810,00020,800115,035Jun 02 02:17 PM